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ABSTRACT
Background
Checkpoint kinase 2 (CHEK2) averts cancer development by promoting cell cycle arrest and
activating DNA repair in genetically damaged cells. Previous investigation has established a role
for the CHEK2 gene in breast cancer aetiology, but studies have largely been limited to the rare
1100delC mutation. Whether common polymorphisms in this gene influence breast cancer risk
remains unknown. In this study, we aimed to assess the importance of common CHEK2 variants
on population risk for breast cancer by capturing the majority of diversity in the gene using
haplotype tagging single nucleotide polymorphisms (tagSNPs).
Methods and Findings
We analyzed 14 common SNPs spanning 52 kilobases (kb) of the CHEK2 gene in 92 Swedish
women. Coverage evaluation indicated that these typed SNPs would efficiently convey
association signal also from untyped SNPs in the same region. Six of the 14 SNPs predicted well
both the haplotypic and single SNP variations within CHEK2. We genotyped these six tagSNPs
in 1,577 postmenopausal breast cancer cases and 1,513 population controls, but found no
convincing association between any common CHEK2 haplotype and breast cancer risk. The
1100delC mutation was rare in our Swedish population—0.7% in cases and 0.4% in controls—
with a corresponding odds ratio for carriers versus noncarriers of 2.26 (95% confidence interval,
0.99–5.15). Estimates of the population frequency and the odds ratio of 1100delC indicate that
our sample is representative of a Northern European population.
Conclusions
Notwithstanding the involvement of the CHEK2 gene in breast cancer aetiology, we show
that common polymorphisms do not influence postmenopausal breast cancer risk.
The Editors’ Summary of this article follows the references.
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Breast cancer is overall the most common cancer in women
worldwide [1]. Twin and family studies have clearly demon-
strated the importance of genetic contribution to breast
cancer risk [2,3]. Genetic studies of familial breast cancer
have identiﬁed several high-penetrance mutations in genes
such as BRCA1 and BRCA2, but these mutations contribute
little to risk at the population level due to their low
prevalence. Whilst genetic risk factors for breast cancer in
women not carrying any high-penetrance mutations are
largely unknown, a polygenic model has been suggested to
account for residual familial risk [4], which anticipates small
effects of low-penetrance genetic risk variants in combina-
tion with environmental inﬂuence.
CHEK2, encoding a cell-cycle checkpoint kinase, is a strong
candidate gene for cancer susceptibility. Following phosphor-
ylation of CHEK2 by ATM after DNA damage, the activated
CHEK2 protein phosphorylates p53, Cdc25, and BRCA1,
thereby arresting the cell cycle and activating DNA repair [5–
8]. As recently veriﬁed, the cellular surveillance system for
DNA damage-checking and repair plays an important role in
averting cancer development [9,10].
An association between the CHEK2*1100delC variant and
breast cancer risk was initially established in breast cancer
families without BRCA1 or BRCA2 mutations [11,12]. This
deletion, ﬁrst detected in a breast cancer case with a family
historyoftheLi-Fraumenisyndrome [13],leadstoa premature
terminationoftranslationthatabolishesCHEK2kinaseactivity
[14]. Most subsequent population studies of the 1100delC
mutation included few carriers and found no signiﬁcant
association with breast cancer risk [12,15–23]. Recently, the
association between the 1100delC and breast cancer suscepti-
bilitywasconvincingly replicated ina pooled analysis of 10,860
unselected cases and 9,065 controls from ten studies in ﬁve
countries [24]. In addition, a more recent study has further
demonstrated that CHEK2*1100delC confers an even higher
lifetime risk in women with a family history of bilateral breast
cancer [25]. Two other putatively functional CHEK2 single
nucleotide polymorphisms (SNPs), IVS2þ1G-A and I157T, have
been studied in relation to breast cancer risk. Some groups
have found an increased risk of breast cancer associated with
these variants [15,23,26,27], whilst others have not [16,28,29].
These polymorphisms are rare and could only make a limited
contribution to the genetic risk for breast cancer at the
population level. Of the two common CHEK2 polymorphisms
studied so far, neither was associated with breast cancer risk
[30]. Thus,whether common variants inCHEK2 are involved in
breast cancer aetiology remains unknown.
To address this question, we analyzed the association
between common haplotypes in the CHEK2 gene and breast
cancer risk in a well-deﬁned Swedish population consisting of
1,577 breast cancer cases and 1,513 controls. In addition, we
explored interactions between CHEK2 variation and hor-
mone-related risk factors for breast cancer. For comparison
with other populations, we also genotyped 1100delC in the
entire set of cases and controls.
Methods
Study Population
This study builds on an earlier population-based Swedish
case-control study of postmenopausal breast cancer [31–35],
with a study base consisting of all Swedish-born women
between 50 and 74 years of age that were resident in Sweden
between October 1993 and March 1995. During that period,
we identiﬁed all breast cancer cases at diagnosis through the
six regional cancer registries in Sweden, to which reporting of
all malignant tumours is mandatory. We randomly selected
controls from the Swedish Registry of Total Population that
matched the cases in 5-y age strata. Of the eligible cases
(3,979) and controls (4,188), 3,345 (84%) cases and 3,454
(82%) controls participated in the initial questionnaire-based
study providing detailed information about menopausal
hormone use, reproductive history, and other lifestyle factors.
From this initial study, we randomly selected 1,500 cases
and 1,500 age-frequency matched controls among the
postmenopausal participants without any previous malig-
nancy (except carcinoma in situ of the cervix or non-
melanoma skin cancer). With the intention of increasing
statistical power in subgroup analyses, we further selected all
remaining cases and controls (191 cases and 108 controls)
who had used menopausal hormones (oestrogen only or any
combination of oestrogen and progestin) for at least 4 y, and
all (110 cases and 104 controls) with self-reported diabetes
mellitus. Additionally, 345 controls that were shared between
the initial breast cancer study and an endometrial cancer
study with same inclusion criteria were added to our control
sample. In total, we selected 1,828 cases and 2,057 controls.
Upon providing informed consent, participants donated
whole blood. We collected archived parafﬁn-embedded, non-
cancerous tissue samples for deceased breast cancer cases as
well as for those breast cancer cases that declined to donate
blood but consented to our use of the tissue. We obtained
blood samples and archived tissue samples for 1,321 and 275
breast cancer patients, respectively, and blood samples from
1,524 controls. Reasons for nonparticipation included a lack
of interest in research or a negative attitude towards genetic
research, old age, and severe disease or death. For deceased
cases and cases that consented to our access to tissue, the
major reason for nonparticipation was unwillingness or lack
of time at the respective pathology departments to retrieve
the tissue. Population-based participation rates (taking into
account the proportion that did not participate in the
questionnaire study) for cases and controls were 73% and
61%, respectively.
This study was approved by the Institutional Review Boards
in Sweden and at the National University of Singapore.
DNA Isolation
DNA was extracted by the Swegene laboratories in Malmo ¨
(Sweden) from 4 ml of whole blood using the QIAamp DNA
Blood Maxi Kit (Qiagen, Valencia, California, United States)
according to the manufacturer’s instructions. From non-
malignant cells in parafﬁn-embedded tissue, we extracted
DNA using a standard phenol/chloroform/isoamyl alcohol
protocol [36]. We successfully isolated DNA from 1,318
(blood) and 272 (tissue) breast cancer patients, and from
1,518 controls.
SNP Markers and Genotyping
We selected SNPs in the CHEK2 gene and its 5-kb ﬂanking
sequences from dbSNP (build 123, http://www.ncbi.nlm.nih.
gov/SNP) and Celera databases, aiming for an initial marker
density of at least one SNP per 5 kb. SNPs were genotyped
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Diego, California, United States) following the manufac-
turer’s instructions. Brieﬂy, multiplex primer extension
assays were designed with the SpectroDesigner software. As
template, 5 ng of genomic DNA was used in a multiplex PCR
reaction. The PCR product was further puriﬁed before the
primer extension reaction to generate allele-speciﬁc base
extension products. The base-extension products were
detected in the MassARRAY time-of-ﬂight mass spectrometry
(MALDI-TOF) system (Sequenom) to determine genotypes.
All genotyping results were generated and checked by
laboratory staff unaware of case-control status. Only SNPs
for which more than 85% of the samples gave a genotype call
were used in further analyses. We genotyped 200 randomly
selected SNPs in the 92 control samples using both the
Sequenom system and the BeadArray system from Illumina
(San Diego, California, United States). The genotype con-
cordance was over 99.5%, suggesting high genotyping
accuracy.
Linkage Disequilibrium Characterization and TagSNP
Selection
To characterize the linkage disequilibrium (LD) pattern, we
calculated pairwise D9 and R
2 values using two-SNP hap-
lotypes inferred via the EH plus program [37]. We recon-
structed haplotypes using the PLEM algorithm [38]
implemented in the tagSNPs program [39], and selected
tagSNPs based on the Rh
2 coefﬁcient. Rh
2 is the squared
correlation between true haplotype dosage (number of copies
of a haplotype) and the haplotype dosage predicted by
tagSNPs. We chose tagSNPs so that common SNP genotypes
and common haplotypes were predicted with an Rh
2 value of
0.8 or higher [40]. In order to evaluate our tagSNP perform-
ance in capturing unobserved SNPs within CHEK2, and to
assess whether we needed a denser set of markers, we
performed the SNP-dropping analysis [41]. In brief, each of
the 14 genotyped SNPs was dropped in turn, and tagSNPs
were selected from the remaining 13 SNPs so that their
haplotypes predicted the 13 SNPs with an R
2 value of 0.9 [42].
A slightly more stringent value of 0.9 was used here, as we
were predicting only SNPs and not haplotypes with our
tagSNPs. We then estimated how well the tagSNP haplotypes
of the remaining 13 SNPs predicted the dropped SNP, an
evaluation that can provide an unbiased and accurate
estimate of tagSNP performance [43]. This method assumes
the markers to be a random selection of the polymorphisms
in the gene. However, some intervals between adjacent
genotyped SNPs exceeded 5 kb. We therefore employed
additional tests for these intervals. If the tagSNPs selected
using only the set of SNPs on one side of the interval
predicted the individual SNPs on the other side sufﬁciently
well, then we judged the coverage to be adequate. We had ﬁve
intervals greater than 5 kb, thus ten sets of predictions. One
of these ten was ignored, as there were only two SNPs to the
left of the gap.
Statistical Analyses
We ﬁrst conducted the haplotype-based association anal-
ysis, since the tagSNPs were chosen primarily such that their
haplotypes can accurately predict common SNPs in the gene.
Our testing strategy was to ﬁrst ﬁt a single model and to assess
for each stratum the haplotype-trait association as a global
likelihood ratio test (on 7 degrees of freedom). The global test
corresponds to carrying out seven tests on 1 degree of
freedom each, and applying a correction for multiple
hypothesis testing. Only if the global test was signiﬁcant did
we proceed to testing individual haplotype contrasts, adjust-
ing for multiple testing [44]. We ﬁrst computed expected
haplotype dosage using haplotype frequencies estimated for
cases and controls combined, assuming Hardy-Weinberg
equilibrium (HWE). We then included the haplotype dosage
as a covariate in a logistic regression model conditioned on
the variables used for sampling: age (5-y age groups),
menopausal oestrogen only use (never, , 4y ,o r  4 y),
menopausal oestrogen and progestin use (never, , 4y ,o r
  4 y) and self-reported diabetes mellitus (yes or no). The
appropriateness of the approach, which in imputing hap-
lotypes does not condition on disease status and the
nonrandom ascertainment scheme, is argued for by Stram
et al. [39]. That is, when Rh
2 values are high, as is the case here,
point and interval estimates obtained by this approach will be
reasonably accurate. Confounding has been deﬁned as the
presence of a common cause to the exposure and the
outcome [45], and we believe that the lifestyle and repro-
ductive breast cancer risk factors, shown in Table 1, are
unlikely to cause genetic variation in CHEK2. However, to
assess whether the risk factors could be intermediates in the
causal pathway between CHEK2 and breast cancer, we tested
whether there was an association between the tagSNPs and
any of the risk factors among the randomly sampled controls
using a Kruskal-Wallis test. We also assessed the associations
between groups of haplotypes and breast cancer risk. Since
there is no biological reason to cluster haplotypes on the basis
of their frequency, we employed a Bayesian association
mapping approach [46] that clusters haplotypes according
to their allelic similarity.
Results
Study Population
Selected characteristics of the participants in the parent
questionnaire study and the current genetic study are
summarized in Table 1. The distribution of nongenetic
factors among cases and controls in the current study were
comparable to those in the parent study and reﬂected
established associations [47,48]. The exceptions were long-
term menopausal hormone use and diabetes mellitus, which
had been consciously oversampled into the current study.
Cases who donated a tissue sample were on average 1.5 y
older and were more likely to have been diagnosed with stage
2 or more advanced cancers (p , 0.0001) compared to cases
who donated a blood sample. However, no signiﬁcant
differences in genotype frequencies were evident between
cases who participated via blood or tissue samples (unpub-
lished data). Furthermore, genotype frequencies were similar
between tumours cm or smaller in diameter without lymph
node involvement and tumours larger than 2 cm or with
spread to regional lymph nodes (unpublished data).
LD Pattern and Coverage Estimation
Of 34 successfully genotyped SNPs in CHEK2, 23 were
polymorphic (Figure 1 and Table 2), but ﬁve of them showed a
signiﬁcant deviation (p , 0.01) from HWE and were therefore
excluded from further analyses. The ﬁve problematic SNPs
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several homologous pseudogenes [49]. Of the remaining 18
polymorphic SNPs, 14 were common (here deﬁned as having
a minor allele frequency [MAF] of at least 0.03) and were
therefore used to characterize the LD pattern and haplotype
structure within CHEK2. The 14 SNPs spanned 52 kb of the
gene, which yielded a mean and median density of one SNP
per 4 kb and 3.2 kb, respectively. The D9 pattern (Figure 1)
suggested strong LD across CHEK2 without extensive
recombination, and we therefore treated the whole gene as
Figure 1. Exon, SNP, and LD Information for CHEK2
Lane 1 (Chr): Physical position on chromosome 22. Lane 2 (CHEK2): Exon locations. Lane 3 (dbSNP): SNPs downloaded from dbSNP build 124. Lane 4
(Genotyped): SNPs genotyped in our study and their respective frequencies in 92 controls. Accession numbers are given for the 14 common SNPs (MAF
  0.03) that were in HWE, tagSNPs are marked with asterisks. LD grid: pairwise D9 between the 14 common SNPs.
DOI: 10.1371/journal.pmed.0030168.g001
Table 1. Selected Characteristics of the Postmenopausal Sporadic Breast Cancer Cases and Controls Participating in the Present Study
Compared to All Who Answered the Questionnaire in the Parent Study
Category Characteristic Parent Study Present Study
Number of
Cases/Controls
Cases Controls Number of
Cases/Controls
Cases Controls
Age and parity data, case
numbers, and mean 6
standard deviation
Age (y) 2,817/3,111 63.4 6 6.7 64.3 6 6.5 1,577/1,513 63.3 6 6.5 63.1 6 6.4
Age at menarche (y) 2,557/2,832 13.5 6 1.4 13.6 6 1.4 1,430/1,385 13.5 6 1.4 13.5 6 1.4
Age at menopause (y) 2,802/3,093 50.4 6 3.5 50.0 6 3.9 1,567/1,500 50.4 6 3.5 50.0 6 4.0
Recent BMI (kg/m
2)
a 2,802/3,065 25.8 6 4.2 25.5 6 4.2 1,568/1,492 25.8 6 4.1 25.5 6 4.2
Age at first birth (y) 2,373/2,753 25.3 6 4.9 24.6 6 4.6 1,339/1,366 25.4 6 4.9 24.7 6 4.7
Parity 2,817/3,110 1.8 6 1.2 2.1 6 1.4 1,577/1,513 1.8 6 1.2 2.2 6 1.3
Duration of menopausal
hormone use, case numbers,
and percentages
0 y 1,978/2,467 71.4 80.8 1,047/1,083 67.0 72.7
, 4 y 405/ 330 14.6 10.8 206/ 190 13.2 12.8
  4 y 389/ 256 14.0 8.4 309
b/ 216
b 19.8 14.5
History, case numbers,
and percentages
Self-reported diabetes mellitus (yes/no) 2,810/2,652 6.0 6.1 1,575
b/1,398
b 9.0 7.8
Family history (yes/no)
c 2,744/2,607 16.0 9.2 1,538/1,376 16.0 9.2
aOne year prior to diagnosis.
bLong-term users of menopausal hormones and women with diabetes mellitus were oversampled.
cFamily history was defined as having at least one first-degree relative with breast cancer.
BMI, body mass index.
DOI: 10.1371/journal.pmed.0030168.t001
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reconstruction. We identiﬁed a total of 31 haplotypes from
the 14 SNPs, six of which were common (i.e., had an estimated
population frequency of at least 0.03) and accounted for 81%
of the chromosomes (Table 3). We selected six tagSNPs from
the 14 common SNPs (Figure 1 and Table 2) that could
efﬁciently and accurately predict the eight remaining
common SNPs and the six common haplotypes within CHEK2
with an average Rh
2 of 0.94.
Four of the 34 typed CHEK2 SNPs were nonsynonymous
coding polymorphisms (Table 2). None of these polymor-
phisms were common and, except for the 1100delC mutation,
were not analyzed further.
Since one cannot assume that tagSNPs capture non-
genotyped SNPs as efﬁciently as genotyped SNPs [50], we
used the SNP dropping method [41] to evaluate tagSNP
performance. We found that the dropped SNPs were
captured with an average R
2 of 0.93, with 13 of the 14
dropped SNPs (93%) having an R
2 greater than 0.75.
Therefore, the six selected tagSNPs could efﬁciently capture
not only all the genotyped but also unobserved common SNPs
within CHEK2. Some intervals between adjacent SNPs
exceeded 5 kb. We found the average proportion of the
variance on one side of the intervals captured by tagSNPs
chosen from the other side was at least 0.68 and averaged
Table 2. Summary Data on 34 SNPs in CHEK2 and Its 5-kb Flanking Sequences Successfully Genotyped in 92 Swedish Controls
SNP
Number
dbSNP
Name
Region Amino Acid Change/
Conserved SNP
a
Position
b Alleles
c Minor Allele
Frequency
d
HWE
p-Value
e
tagSNPs
1 rs5762743 39 downstream 27404217 A 0 –
2 rs6005836 39 downstream 27404332 A 0 –
3 rs2881500 39 downstream 27405080 G/A 0.500 0.000
4 rs2881501 39 downstream 27405104 G 0 –
5 rs3963404 Intron 16–17 27409529 C/T 0.500 0.000
6 rs4035547 Intron 16–17 27409670 C 0 –
7 rs17882942 Exon 16 V483L 27409685 C 0 –
8 rs17883172 Exon 16 K472E 27409718 G 0 –
9 rs8135424 Intron 15–16 27410346 G/A 0.116 0.054 TAG1
10 rs2346874 Intron 15–16 27410423 C/T 0.494 0.000
11 rs4035551 Intron 15–16 27410584 G/A 0.500 0.000
12 rs5762746 Intron 15–16 Conserved 27412677 T/C 0.494 0.000
13 rs5762749 Intron 14–15 27415591 C/G 0.375 0.78 TAG2
14 rs2267130 Intron 9–10 27424308 C/T 0.495 0.92
15 rs743184 Intron 9–10 27427521 T/C 0.352 0.21
16 rs743185 Intron 9–10 27427771 C/T 0.117 0.21 TAG3
17 rs2073326 Intron 9–10 27430081 A/C 0.016 0.87
18 rs1884816 Intron 8–9 Conserved 27431287 T/C 0.124 0.19
19 rs1884817 Intron 8–9 Conserved 27431499 G/C 0.139 0.59
20 rs5752776 Intron 7–8 27432783 G/A 0.337 0.67
21 rs6005843 Intron 7–8 27432998 T/C 0.023 0.83
22 rs6005846 Intron 6–7 27440386 A/C 0.011 0.92
23 rs2347443 Intron 6–7 27443774 G/C 0.148 0.44
24 rs17879961 Exon 6 I157T 27445641 T/C 0.006 0.96
25 rs4525795 Intron 4–5 27450390 C 0 –
26 rs12627843 Intron 4–5 27450739 G 0 –
27 rs13056673 Intron 4–5 27453934 T 0 –
28 rs738722 Intron 4–5 27454566 C/T 0.319 0.14 TAG4
29 rs17883862 Exon 4 P85L 27455010 C 0 –
30 rs5762764 59 UTR-intron 3–4 27457544 A/G 0.330 0.83
31 rs5762765 59 UTR-intron 3–4 27457587 G/C 0.292 0.55 TAG5
32 rs2236141 59 UTR-exon 3 Conserved 27462424 C/T 0.122 0.74
33 rs2236142 59 UTR-exon 3 Conserved 27462498 C/G 0.313 0.65 TAG6
34 rs7292212 59 UTR-exon 3 27462726 C 0 –
aNonsynonymous variant amino acid exchange or polymorphism located in conserved sequence between human-mouse or human-rat or both.
bdbSNP build 124.
cMajor alleles given first and minor alleles second.
dIn 92 controls.
eFrom v
2 test in 92 controls.
DOI: 10.1371/journal.pmed.0030168.t002
Table 3. Common Haplotypes Reconstructed Using 14 SNPs in
CHEK2
Haplotypes Haplotype Frequency
a Rh
2b
GGTCCTGAGTAGCC 0.271 0.964
GCCTCTGGGCGCCC 0.190 0.938
ACCTCTGGGCAGCC 0.117 0.995
GCCTCTGGGCGCTG 0.103 0.887
GCTTTCCGCCAGCG 0.096 0.975
GGTCCTGAGCAGCG 0.030 0.854
aIn 92 controls.
bRh
2 quantifies how well we can predict the number of copies of haplotypes an individual
carries using the six tagSNPs.
DOI: 10.1371/journal.pmed.0030168.t003
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considered were a much greater distance apart than the
polymorphisms in the intervals of interest. Thus we consider
such gaps to present little problem and conclude that our
gene is sufﬁciently densely genotyped and that our tagSNPs
effectively capture the common variation present in the gene.
Association Analyses
We successfully genotyped the six tagSNPs in 1,577 breast
cancer cases and 1,513 controls. All six tagSNPs were in HWE
among the controls (unpublished data). We assessed, among
the randomly selected controls, whether any of the tagSNPs
were associated with the lifestyle and reproductive breast
cancer risk factors shown in Table 1. TAG2 and TAG4 were
statistically associated with parity (p ¼ 0.029 and p ¼ 0.009,
respectively), which showed a statistically signiﬁcant trend for
allelic dose (TAG2, p ¼ 0.006; TAG4, p ¼ 0.0002).
We identiﬁed 19 rare (Table S1) and seven common
haplotypes from the six tagSNPs (Table 4). The 19 rare
haplotypes were collapsed into a single group in the
association analyses. One additional common haplotype was
identiﬁed in the full set of controls, which was not identiﬁed
in the preliminary 92 controls. A global test of association,
including all common haplotypes and the 19 rare haplotypes
as one group in the model, was not statistically signiﬁcant
(likelihood ratio test, p ¼ 0.19). Table 4 presents odds ratios
(ORs) and conﬁdence intervals (CIs) for tagSNP haplotypes
using the most common haplotype (haplotype 1) as reference.
None of the common haplotypes increased the risk of breast
cancer, but the comparison between the group of 19 rare
haplotypes against the reference showed a slight association
with breast cancer risk (OR 1.24; 95% CI, 1.02–1.51), which
did not, however, carry over to the global test, in which
multiple testing has been formally accounted for. After
excluding the 1100delC carriers (n ¼ 28) from the analysis,
this association decreased (OR 1.20; 95% CI, 0.98–1.47), whilst
the odds ratios for the common haplotypes remained
unchanged. Comparing carriers to noncarriers of each
haplotype, instead of using haplotype 1 as reference, did
not substantially affect the results (unpublished data).
Considering only breast cancer cases eventually diagnosed
with a second breast cancer (n¼72) similarly did not provide
any convincing association (Table S2). These ﬁndings
remained unaltered after restricting the analyses to the
randomly selected cases and controls or after including other
breast cancer risk factors, including parity, as covariates in
the logistic regression models.
We stratiﬁed the haplotype analysis by several breast
cancer risk factors: ﬁrst-degree family history, body mass
index, age at ﬁrst birth, menopausal hormone use, and parity
(Tables S3–S7, respectively). None of the stratiﬁed analyses
yielded a signiﬁcant (a ¼ 0.05) global test of association.
The 19 rare haplotypes accounted for approximately 20%
of the chromosomes. Clustering haplotypes based on their
allelic similarity did not provide an indication of a disease
susceptibility locus in the region.
We also tested the association between tagSNP genotypes
and breast cancer risk, overall (Table S8) and stratiﬁed by
other risk factors (unpublished data), but no additional
compelling results emerged. Adjusting the models including
TAG2 or TAG4, for parity did not change our results.
Analysis of CHEK2*1100delC
The 1100delC mutation, genotyped in 1,510 cases and 1,334
controls, was rare in our Swedish population, with a
frequency of 0.4% in the controls (HWE, p ¼ 0.89). The
deletion was slightly more common in the cases (0.7%) than
in the controls, and the corresponding age- and sampling
scheme-adjusted odds ratio for carriers versus noncarriers
was 2.26 (95% CI, 0.99–5.15) (Table 5). The 1100delC was
exclusively carried on rare haplotypes, which may explain the
marginally signiﬁcant association between the group of 19
rare haplotypes and breast cancer risk (Table 4).
Discussion
Our extensive linkage disequilibrium mapping association
study did not provide support for an association between
common variations in CHEK2 and breast cancer risk. The
1100delC mutation was more common in cases than in
controls in our study population, but the difference was not
statistically signiﬁcant. The genotype frequencies were
Table 4. Common Haplotypes Reconstructed Using Six tagSNP
in CHEK2 in Relation to Breast Cancer Risk
Haplotype
Number
Haplotypes Estimated Haplotype
Frequency
a
OR (95% CI)
b
Cases
(n ¼ 1,571)
Controls
(n ¼ 1,513)
1 GCCCCC 0.223 0.241 1.00 (Reference)
2 GGCTGC 0.231 0.230 1.07 (0.92–1.26)
3 GCCCCG 0.140 0.129 1.13 (0.93–1.37)
4 ACCCGC 0.113 0.104 1.20 (0.98–1.46)
5 GCTCGG 0.089 0.088 1.10 (0.88–1.36)
6 GGCCGC 0.052 0.060 0.94 (0.72–1.24)
7 GCCCGC 0.027 0.034 0.87 (0.61–1.26)
19 rare
c 0.125 0.114 1.24 (1.02–1.51)
The global p-value for these data was 0.19, based on a likelihood ratio test with 7 degrees
of freedom.
aInformation is provided on at least one out of six tagSNPs.
bAnalyses were conditioned on age (5-y age groups), menopausal oestrogen only use
(never, , 4y ,o r  4 y), use of oestrogen in combination with progestin (never, , 4y ,o r 
4 y) and diabetes mellitus (yes or no).
cThese 19 rare haplotypes were combined into a single group. Each haplotype is below
3% in frequency among the controls.
DOI: 10.1371/journal.pmed.0030168.t004
Table 5. Overall Association of the CHEK2*1100delC Mutation
with Breast Cancer Risk
1100delC
Genotype
Number of
Cases/Controls
a
OR (95% CI)
b
C/C 1,490/1,326 1 (Reference)
C/  19/8 2.13 (0.92–4.89)
 /  1/0 –
C/  and  /  20/8 2.26 (0.99–5.15)
aGenotype frequencies conformed to Hardy-Weinberg proportions.
bAnalyses were conditioned on age (5-y age groups), menopausal oestrogen only use
(never, , 4y ,o r  4 y), use of oestrogen in combination with progestin (never, , 4y ,o r 
4 y,) and diabetes mellitus (yes or no).
DOI: 10.1371/journal.pmed.0030168.t005
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CHEK2 Haplotypes and Breast Cancer Risksimilar to those reported in other populations, thus conﬁrm-
ing that our study population is representative of other
Northern European populations.
The population on which our study was based is relatively
large, well deﬁned, and genetically homogenous. We were
able to cover the majority of common variations in the
CHEK2 gene by genotyping a relatively dense map of markers.
We had detailed information about hormone-related risk
factors for breast cancer that allowed us to explore gene-
environment interactions. We also assessed the statistical
power of our study. Until now, the power evaluations of
CHEK2 genetic studies have been carried out under the
assumption that the genetic risk allele is being directly tested
[17]. This approach misleadingly overestimates power, be-
cause the susceptibility allele is rarely tested directly. Our
detailed understanding of the LD pattern across CHEK2
allowed us to overcome these limitations and estimate power
more accurately. To estimate power we used a method
described by Chapman et al. [42], which assumes codominant
effects at an unobserved locus (assuming 80% power, an a-
value of 0.05, and R
2 ¼ 0.9 for the ability of haplotypes to
predict the allele count at the causal locus). We estimate that
our study should be able to detect a disease susceptibility
locus with an odds ratio of 1.23 if its MAF is 0.5, of 1.25 if
MAF ¼ 0.35, of 1.32 if MAF ¼ 0.15, or of 1.55 if MAF ¼ 0.05.
Therefore, given the comprehensive coverage of common
genetic variants within CHEK2 by our tagSNP approach, it is
unlikely that any common disease allele of at least moderate
effect was missed in our study.
Selection bias could have arisen in this study, as non-
participation was related to severe disease or death. However,
CHEK2 genotype frequencies were not signiﬁcantly different
between cases donating tissue samples, representing more ill
or deceased patients, and cases donating blood samples. This
nonparticipation thus affected only the generalizability of
our study.
The 1100delC variant has not previously been studied in
the Swedish population. The variant is rare [15–21,23],
except in a few Northern European populations such as
Finland and the Netherlands, where moderate frequency of
1% or above has been observed [11,12,22]. The low
population frequency of 1100delC in the Swedish population
is therefore generally in line with previous data. Further-
more, the corresponding odds ratio for carriers versus
noncarriers was 2.26 (95% CI, 0.99–5.15), which is also
consistent with the results from other Northern European
populations [22,24]. Taken together, the results of our
1100delC analysis conﬁrm that our case-control sample is
representative of a Northern European population.
A few pathogenic variants have been identiﬁed by
sequencing CHEK2, examples of which are 1100delC and
I157T [13]. Association analyses of these variants in various
different populations suggest that these variants are
associated with moderate risk for breast cancer and have a
low population frequency [15,23,24,26,27]. The pathological
effect of 1100delC was suggested to be due to haploinsufﬁ-
ciency caused by the lost function of the 1100delC truncated
protein [51]. In contrast, by introducing a nonconservative
amino acid change into the forkhead-associated domain of
CHEK2, I157T may produce a dominant-negative effect by
forming heterodimers with wild-type CHEK2 protein [27].
The I157T mutation could also have a pathological effect by
producing a defective protein for binding and phosphor-
ylating its downstream target, Cdc25A, and for binding p53
and BRCA1 [15]. Given the fact that CHEK2 plays a central
role in the DNA damage checkpoint and apoptosis pathways
[52], the modest effect of the CHEK2 pathogenic variants is
surprising. It is however most likely due to the functional
redundancy in the crucial DNA damage checkpoint pathway
and thus the compensation of defect in CHEK2 function by
other members of the pathway. This mechanism was
suggested in a recent study showing that the normal
degradation of Cdc25A is was shown to be maintained in
the carriers of the 1100delC variant [51]. Our association
study supports other reports [30] indicating that, besides the
known pathogenic coding variants, it is unlikely that other
common coding or noncoding variants play a signiﬁcant
role in a predisposition to breast cancer. This is consistent
with the notion discussed by Cybulski et al. [15] that there
are three classes of risk genes for breast cancer: a class of
genes in which mutations are rare but confer a very high
relative risk (including BRCA1 and BRCA2); a class in which
variants are common but confer only modest risk (few if any
such genes have been conﬁrmed to date); and a class
(including CHEK2) in which mutations are rare but
associated with only modest risk. Although the idea is
speculative, CHEK2 may exercise a pleiotropic effect as a
central player in the DNA damage checkpoint and apoptosis
pathways on other biological processes than its role in
carcinogenesis, and this may provide necessary selection
pressure to maintain its functional variants at a low
population frequency.
To our knowledge, this is the most comprehensive
evaluation of the association between the genetic variation
within CHEK2 and postmenopausal breast cancer risk.
However, despite the role of the CHEK2 gene in breast
cancer aetiology, we conclude that common variations in
CHEK2 do not affect breast cancer risk, at least not in the
Swedish population. On the other hand, our study cannot
exclude the possible inﬂuence of rare genetic variants in
CHEK2, such as the CHEK2*1100delC, on breast cancer risk.
Investigation of such rare risk alleles in a population-based
design requires a much larger sample size than the one
utilized in the present study.
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Editors’ Summary
Background. Approximately 5% of breast cancer patients have a strong
familial risk for the disease. In these families, multiple family members
are usually affected, often at an early age (before they are 35). Rare
inherited variants in two genes, BRCA1 and BRCA2, are responsible for the
high breast cancer risk in most of these ‘‘breast cancer families.’’ Among
the other 95% of women with breast cancer who are not known to have
inherited one of these high-risk variants, there may still be some
inherited susceptibility to the disease: about 10% of women have a
‘‘moderate’’ family history of breast cancer. The inherited genetic factors
that are responsible for the more common but weaker susceptibility to
breast cancer are so far mostly unknown. These factors could, for
example, be common variants in many different genes, each of which on
their own cause only a moderately raised risk (although more common
variants of the BRCA1 and BRCA2 genes do not seem to be associated
with breast cancer).
Why Was This Study Done? CHEK2 is another gene that has been
associated with familial breast cancer. In some breast cancer families
without mutations in BRCA1 and BRCA2, a specific variant of CHEK2
(called 1100delC, indicating a deletion at position 1100) occurred
frequently in patients with breast cancer. The association between this
particular CHEK2 variant and an increased risk of breast cancer was
confirmed in a large study that looked at approximately 10,000 patients
with breast cancer and 10,000 controls. However, the 1100delC variant of
CHEK2 is rare, and scientists want to know whether more common
variants of the gene were associated with breast cancer. A number of
previous studies that looked at two common variants of CHEK2 had not
given consistent results. This study used six common variants to predict
all common variants of CHEK2 in a group of postmenopausal Swedish
women and tested whether any of the six variants were associated with
the women having breast cancer.
What Did the Researchers Do and Find? They identified the six
common variants by analyzing the DNA of the CHEK2 gene in 92 Swedish
women. They then compared the frequency of these common variants
between approximately 1,500 women with breast cancer and 1,500
women of the same age and similar lifestyles without breast cancer. They
found no association between any of the common variants and the
likelihood of the women having breast cancer.
What Do These Findings Mean? This study suggests that Swedish
women (or those of Northern European descent who have a similar
genetic inheritance) who have any of the common variants of the CHEK2
gene do not have a raised risk of getting breast cancer. However, this
finding might not apply in other populations. As in previous studies, this
study also found a raised risk of breast cancer for women who carried the
rare 1100delC variant, but the study was too small to test whether there
are other rare variants that might also predispose to breast cancer.
Overall, scientists have not yet found many common gene variants that
increase the risk of getting cancer. But, to test conclusively for
associations between genetic variants, both common and rare, and
cancer, very large studies will be needed. Understanding how a person’s
genetic make-up and their environment and lifestyle influence their risk
for certain cancers remains a challenge.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030168.
  Risk factors for breast cancer from the American Cancer Society
  Summary of information on the CHEK2 gene from the US National
Center for Biotechnology Information
  Information on Breast Cancer molecular biology and genetics from
Cancer Research UK
  Information on breast cancer genetics from the UK Public Health
Genetics Unit
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